{"id":7788,"date":"2026-02-24T06:08:15","date_gmt":"2026-02-24T06:08:15","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/glp-1-semaglutide-cagrilintide\/"},"modified":"2026-04-09T14:25:52","modified_gmt":"2026-04-09T21:25:52","slug":"glp-1-c-glp-1-s","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/glp-1-c-glp-1-s\/","title":{"rendered":"GLP-1 C + GLP-1 S \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to GLP-1 C + GLP-1 S product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on these compounds \u2014 for educational purposes only<\/p>\n

\nC Mechanism of Action at Amylin Receptors<\/summary>\n
\n

C is an acylated long-acting analog of amylin that binds to amylin receptor subtypes (AMY1 and AMY3) and calcitonin receptors. Its mechanism of action involves activation of receptor activity-modifying proteins (RAMPs) complexed with the calcitonin receptor, triggering intracellular cAMP signaling cascades. The C18 fatty diacid modification enables non-covalent albumin binding, extending the pharmacokinetic half-life in preclinical models. Research compound \u2014 not for human use.<\/p>\n

Hay DL et al. “Amylin: Pharmacology, Physiology, and Clinical Potential.” Pharmacol Rev.<\/em> 2015. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nGLP-1 S GLP-1 Receptor Binding and Signaling<\/summary>\n
\n

GLP-1 S is a GLP-1 receptor agonist featuring an Aib8 substitution and a C18 fatty diacid chain linked via a mini-PEG spacer at Lys26. It activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor, triggering G\u03b1s-mediated cAMP accumulation. The structural modifications confer resistance to DPP-4 enzymatic degradation and enable strong albumin binding, resulting in an extended pharmacokinetic half-life. Research compound \u2014 not for human use.<\/p>\n

Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and GLP-1 S.” Front Endocrinol.<\/em> 2019. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nDual Amylin and GLP-1 Pathway Pharmacology<\/summary>\n
\n

Research into the co-administration of amylin analogs with GLP-1 receptor agonists investigates the convergent signaling pathways in the area postrema, nucleus tractus solitarius, and hypothalamic nuclei. Both amylin and GLP-1 receptors signal through cAMP-dependent pathways in hindbrain neurons, with distinct receptor distributions suggesting complementary rather than redundant receptor engagement. Preclinical models have characterized the pharmacodynamic interactions between these two receptor systems. Research compound \u2014 not for human use.<\/p>\n

Lutz TA. “The interaction of amylin with other hormones in the control of eating.” Diabetes Obes Metab.<\/em> 2013. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to GLP-1 C + GLP-1 S product page Research Library Published research on these compounds \u2014 for educational purposes only C Mechanism of Action at Amylin Receptors C is an acylated long-acting analog of amylin that binds to amylin receptor subtypes (AMY1 and AMY3) and calcitonin receptors. Its mechanism of action involves activation […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7788","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7788"}],"version-history":[{"count":2,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7788\/revisions"}],"predecessor-version":[{"id":8619,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7788\/revisions\/8619"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}